已收盘 11-13 16:00:00 美东时间
+0.090
+3.69%
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 12.9 percent decrease over losses of $(0.31) per share from the same period last year.
11-06 21:34
Protara Therapeutics announced financial results for Q3 2026 and provided updates on its clinical programs. The company expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial for TARA-002 in NMIBC by year-end 2026 and initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027. Enrollment in the STARBORN-1 trial for TARA-002 in LMs is now expected to complete in early 1Q 2027. Protara also completed enrollment ...
11-06 13:00
Protara Therapeutics, Inc. (Nasdaq: TARA) announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 pm ET. A live webcast will be available on the Company’s website, and an archive will be accessible for a limited time. Protara is a clinical-stage biotech company focused on developing therapies for cancer and rare diseases, including its lead candidate TARA-002 for no...
09-08 20:05
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 2.86 percent decrease over losses of $(0.35) per share from the same period last year.
08-11 20:07
Corbus Pharmaceuticals reported progress in its oncology and obesity pipeline, obtaining FDA clearance for the registrational study of CRB-701 in oropharyngeal cancer and completing the last patient visit in the CANYON-1 trial of CRB-913 for obesity. The company also appointed new leadership to strengthen its team. Financially, Corbus reported a net loss of $35 million for the second quarter, with $117.9 million in cash on hand.
08-06 12:00
Corbus Pharmaceuticals Holdings (CRBP) announced the appointment of Leonardo Viana Nicacio as Chief Medical Officer. Nicacio brings over 20 years of pharmaceutical and oncology experience, notably ser...
07-06 20:14
Corbus Pharmaceuticals appoints Dr. Leonardo Viana Nicacio as Chief Medical Officer, bringing extensive experience in solid tumor drug development, including ADCs like TIVDAK® for metastatic cervical cancer. The company is set to initiate the TEMPO-1 registrational study for CRB-701 in 2L oropharyngeal squamous cell carcinoma (OPSCC) this summer. Dr. Nicacio emphasizes advancing CRB-701 and CRB-913 to address unmet needs in oncology and obesity, ...
07-06 12:00
Protara Therapeutics ( ($TARA) ) has issued an announcement. On June 26, 2026, ...
06-30 05:30
Protara Therapeutics ( ($TARA) ) just unveiled an announcement. Protara Therape...
06-16 05:06
$100,000,000Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, dated May 13, 2026, or the Sales Agreement, relating to the sale of shares of our common stock, par value $0.001
05-29 05:20